Search Results - subject:"Inhibitors"

Management of Advanced Breast Cancer: Defining the Role of Anastrozole

Keating, Gillian M.; Goa, Karen L. - In: Disease Management and Health Outcomes 9 (2001) 7, pp. 385-402

Breast cancer is the most common malignancy affecting women and imposes a substantial economic burden on society. Estrogen is thought to play a major role in both the initiation and promotion of hormone dependent breast cancer, and a number of well recognized risk factors for breast cancer...

Persistent link: https://www.econbiz.de/10005448777

Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis: Ontario Ministry of Health Perspective

Marshall, John K.; Pellissier, James M.; Attard, Cheryl L. - In: PharmacoEconomics 19 (2001) 10, pp. 1039-1049

Background: Clinical trials have shown rofecoxib, a selective inhibitor of cyclo-oxygenase-2, to be associated with fewer gastrointestinal complications than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). Objective: To evaluate the potential clinical and economic consequences of...

Persistent link: https://www.econbiz.de/10005449240

Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression: Potential Pitfalls

Hensley, Paula L.; Nurnberg, H. George - In: PharmacoEconomics 19 (2001) 10, pp. 973-982

The American healthcare market is currently estimated at more than $US900 billion with double digit rising costs per year. Psychotropic agent costs have more than kept pace with market increases. Medication acquisition costs are an obvious focus for limiting costs in various care systems....

Persistent link: https://www.econbiz.de/10005449253

Economic and Health-Related Quality of Life Considerations of New Therapies in Parkinson's Disease

Rubenstein, Linda M.; DeLeo, Andrea; Chrischilles, … - In: PharmacoEconomics 19 (2001) 7, pp. 729-752

The progressive disability of Parkinson's disease results in substantial burdens for patients, their families and society in terms of increased health resource use, poorer quality of life, caregiver burden, disrupted family relationships, decreases in social and leisure activities, deteriorating...

Persistent link: https://www.econbiz.de/10005590467

Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension: Economic Evaluation of Ramipril Efficacy In Nephropathy (REIN) Study for Germany from the...

Schadlich, Peter K.; Brecht, Josef Georg; Brunetti, Massimo - In: PharmacoEconomics 19 (2001) 5, pp. 497-512

Background: In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF). Objective: To determine the additional cost per patient-year of chronic...

Persistent link: https://www.econbiz.de/10005590520

The Importance of Achieving Additional Drug Benefits at a Reasonable Cost: A Review of the Fluoxetine Years

Freemantle, Nick; Mason, James - In: PharmacoEconomics 17 (2000) 4, pp. 319-324

depression, the evidence for fluoxetine and for the selective serotonin reuptake inhibitors in general suggest at best a modest …

Persistent link: https://www.econbiz.de/10005243117

ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations

Davie, Andrew P. - In: PharmacoEconomics 17 (2000) 3, pp. 237-243

Economic analysis has been extensively used to guide the use of ACE inhibitors in chronic heart failure. More recently …, it has been used to guide the use of ACE inhibitors after myocardial infarction. The results of major clinical trials … leave us in no doubt that ACE inhibitors are useful in the treatment of patients after myocardial infarction. The results of …

Persistent link: https://www.econbiz.de/10005449244

Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia

Sonnenberg, Amnon - In: PharmacoEconomics 17 (2000) 4, pp. 391-401

dysphagia, depending on treatment with histamine-2-receptor antagonists (H2RAs) or proton pump inhibitors (PPIs). Oesophageal …

Persistent link: https://www.econbiz.de/10005449255

New Generation Aromatase Inhibitors in Breast Cancer: Weighing Out Potential Costs and Benefits

Higa, Gerald M. - In: PharmacoEconomics 17 (2000) 2, pp. 121-132

aromatase inhibitors are discussed in order to assess their potential costs and therapeutic merit. …

Persistent link: https://www.econbiz.de/10005449281

Cote, Isabelle; Gregoire, Jean-Pierre; Moisan, Jocelyne - In: PharmacoEconomics 18 (2000) 5, pp. 435-450

In hypertension, tolerability of drug treatment is important because individuals may see the use of antihypertensive medications as more troubling than their seemingly symptomless disease. This may result in noncompliance and ineffectual long term treatment. In the past 15 years, new...

Persistent link: https://www.econbiz.de/10005449301